Want to see BEAT full AI Analyst Report?
BEAT Stock Chart & Stats
$2.56
$0.00(0.00%)
At close: 4:00 PM EST
$2.56
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.51 - $4.00
Previous CloseN/A
Volume12.23K
Average Volume (3M)995.54K
Market Cap
$31.03M
Enterprise Value$47.48
Total Cash (Recent Filing)$2.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 06, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding55,506,836
10 Day Avg. Volume1,771,289
30 Day Avg. Volume995,536
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)31.08
Price to Sales (P/S)0.00
P/FCF Ratio-5.55
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.17Price Target Upside23.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.36
Revenue Forecast (FY)$976.50K
Bulls Say, Bears Say
Bulls Say
Extended Runway From $11.5M FinancingThe $11.5M underwritten offering raised pro forma cash of about $12.4M, extending runway into 2027. This materially eases immediate financing pressure, enabling completion of pilots, prototype work, initial commercial pilots and AI development without urgent dilution.
Regulatory Foundation With FDA ClearancesTwo FDA clearances establish a durable regulatory foothold for limited commercial launch and validate the core 3D ECG technology. This reduces incremental regulatory risk for adjacent indications and strengthens the company’s position for licensing and health‑system adoption over the medium term.
New Patent Expands Device CapabilitiesThe allowed patent protecting acoustic sensing and thoracic impedance in the chest‑worn device broadens physiologic signal capture, differentiates the platform, and strengthens IP for licensing/OEM deals. That durable technology moat supports expansion into HF and structural markets.
Bears Say
Pre-revenue With Sustained LossesHeartBeam remains pre‑revenue with substantial net losses (~$13M–$21M annually and about $20M TTM). Persistent cash‑based operating losses mean continued dependence on external funding and make the path to self‑sustaining operations contingent on slow commercial adoption and successful clinical outcomes.
Severely Weakened Shareholder EquityEquity declined materially to roughly $0.6M TTM, leaving a minimal capital cushion. A thin balance sheet increases dilution risk, constrains borrowing capacity, and reduces financial flexibility to fund pivotal studies, manufacturing scale or broader commercialization without dilutive financings.
Nasdaq Minimum Bid-price Deficiency RiskThe Nasdaq deficiency notice creates a material listing risk through Dec 28, 2026. Potential delisting would impair access to public capital, raise cost of capital and deter partners or investors, constraining financing options and strategic execution over the coming months.
HeartBeam News
BEAT FAQ
What was Heartbeam, Inc.’s price range in the past 12 months?
Heartbeam, Inc. lowest stock price was $0.51 and its highest was $4.00 in the past 12 months.
What is Heartbeam, Inc.’s market cap?
Heartbeam, Inc.’s market cap is $31.03M.
When is Heartbeam, Inc.’s upcoming earnings report date?
Heartbeam, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 18 days.
How were Heartbeam, Inc.’s earnings last quarter?
Heartbeam, Inc. released its earnings results on May 13, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.135 by $0.015.
Is Heartbeam, Inc. overvalued?
According to Wall Street analysts Heartbeam, Inc.’s price is currently Undervalued.
Does Heartbeam, Inc. pay dividends?
Heartbeam, Inc. does not currently pay dividends.
What is Heartbeam, Inc.’s EPS estimate?
Heartbeam, Inc.’s EPS estimate is -0.09.
How many shares outstanding does Heartbeam, Inc. have?
Heartbeam, Inc. has 55,506,836 shares outstanding.
What happened to Heartbeam, Inc.’s price movement after its last earnings report?
Heartbeam, Inc. reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.135. Following the earnings report the stock price went up 2.97%.
Which hedge fund is a major shareholder of Heartbeam, Inc.?
Currently, no hedge funds are holding shares in BEAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeartBeam Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.17 (23.70% Upside)
$3.17 (23.70% Upside)
Blogger Sentiment
Bullish
BEAT Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.32%
12-Months-Change
Fundamentals
Return on Equity
-1034.04%
Trailing 12-Months
Asset Growth
-56.86%
Trailing 12-Months
Company Description
Heartbeam, Inc.
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.
BEAT Stock 12 Month Forecast
Average Price Target
$3.17
▲(23.70% Upside)
Technical Analysis
Ownership Overview
10.47% Insiders
2.61% Mutual Funds
1.69% Other Institutional Investors
81.15% Public Companies and
Individual Investors